BioNTech and Takara enter license agreement for CAR-T; The FDA has freed another batch of J&J's Covid-19 vaccine
Takara Bio has entered an agreement with BioNTech to license out its RetroNectin platform.
Under the agreement, the German BioNTech will be able to use RetroNetic for the production of cell and gene therapy products, in particular, CAR T cell therapies for the treatment of multiple solid tumors.
The technology allows efficient gene transduction through retrovirus and lentivirus vector and expansion of T-cells. RetroNectin is a recombinant human fibronectin fragment that contains three functional domains: cell-binding, the heparin-binding and the CS-1 sequence. It’s one of the most common standard protocols used for engineered T-cell therapy, Takara says.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
